2026 · Poster Presentation · Amgen · Dermatology
32
Total Publications
4
Abstract/Manuscript
5
Oral Presentation
23
Poster Presentation
2026 · Poster Presentation · R&D · Dermatology
A comparison of stable vs progressive hidradenitis suppurativa: insights from TARGET-DERM HS.
Read more →2026 · Poster Presentation · R&D · Dermatology
The impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM.
Read more →2026 · Poster Presentation · Amgen · Dermatology
Real world characteristics and burden of patients initiating advanced systemic therapy in the TARGET-DERM atopic dermatitis registry.
Read more →2026 · Poster Presentation · Pharma Partner · Gastroenterology
Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.
Read more →2026 · Poster Presentation · Pharma Partner · Gastroenterology
Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO.
Read more →2026 · Poster Presentation · Pharma Partner · Gastroenterology
Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD.
Read more →2026 · Poster Presentation · Pharma Partner · Gastroenterology
Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Ulcerative Colitis: Findings From TARGET-IBD.
Read more →2024 · Abstract/Manuscript · Atopic Dermatitis (AD)
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry.
Read more →2023 · Abstract/Manuscript · R&D
Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non–Muscle-Invasive Bladder Cancer.
Read more →2021 · Oral Presentation · R&D · Methods/Pharmacoepi
Lipids testing trends before and after hospitalization for myocardial infarction among adults in the United States, 2008-2019.
Read more →2020 · Poster Presentation · Pharma Partner · Hepatology
Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH.
Read more →2020 · Abstract/Manuscript · R&D
Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease.
Read more →2020 · Abstract/Manuscript · R&D
Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Co-morbid Diseases.
Read more →2019 · Poster Presentation · Pharma Partner · Hepatology
Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort.
Read more →2019 · Poster Presentation · Emory · Hepatology
Patient Reported Outcomes Among Pediatric Patients with Nonalcoholic Fatty Liver Disease: TARGET-NASH.
Read more →2019 · Poster Presentation · Emory · Hepatology
Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH.
Read more →2019 · Poster Presentation · R&D · Hepatology
The Prescribing Patterns and Use of Statins in Patients with Nonalcoholic Fatty Liver Disease.
Read more →2019 · Poster Presentation · R&D · Hepatology
Opioid use in patients with NAFLD: prevalence and association with comorbidities and disease severity.
Read more →2019 · Poster Presentation · R&D · Hepatology
Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD.
Read more →2019 · Poster Presentation · R&D · Hepatology
Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC).
Read more →2019 · Poster Presentation · R&D · Hepatology
Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US.
Read more →2019 · Oral Presentation · R&D · Hepatology
Incidence of Achieving Weight Loss Goals in Usual Clinical Practice: Results for the TARGET-NASH Observational Cohort.
Read more →2019 · Oral Presentation · R&D · Methods/Pharmacoepi
Lipid testing trends in the US before and after the release of the 2013 ACC/AHA cholesterol guidelines.
Read more →2018 · Poster Presentation · Emory · Hepatology
Characterization of polypharmacy in patients with NAFLD.
Read more →2018 · Poster Presentation · Columbia University Medical Center · Hepatology
Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) with and without Type 2 Diabetes Mellitus (T2DM).
Read more →2018 · Poster Presentation · R&D · Hepatology
Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH.
Read more →2018 · Poster Presentation · R&D · Hepatology
Patient-Reported Indicators of Health and Symptoms in US Patients with Primary Biliary Cholangitis (PBC).
Read more →2018 · Poster Presentation · R&D · Gastroenterology
Development of a Novel Longitudinal Observational Cohort of Adult and Pediatric Patients with Inflammatory Bowel Disease: TARGET-IBD.
Read more →2018 · Oral Presentation · Pharma Partner · Methods/Pharmacoepi
Real-world patterns of romiplostim treatment in adults with primary immune thrombocytopenia in the United States.
Read more →2017 · Poster Presentation · Approval & Commercialization · Hepatology
Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH.
Read more →2017 · Oral Presentation · R&D · Methods/Pharmacoepi